Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 5/20 | 0.38 |
| ▸ | AGXT | P21549 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134443 | 0.86 | IDO1 (0.46) | TSHRIDO1AGXTPTGS2LMNA | |
| SCHEMBL9806222 | 0.81 | TSHR (0.37) | TRPA1ALDH1A1TSHRIDO1AGXT | |
| SCHEMBL1918984 | 0.80 | TDP1 (0.48) | IDO1AGXTPTGS2LMNATP53 | |
| SCHEMBL3149674 | 0.80 | PTPN1 (0.46) | PTGS2LMNATP53CA2 | |
| SCHEMBL1995347 | 0.79 | IDO1 (0.58) | ALDH1A1TSHRIDO1LMNAAPP | |
| SCHEMBL3143263 | 0.78 | PTPN1 (0.44) | LMNATP53CA2 | |
| SCHEMBL8020885 | 0.78 | ESR1 (0.48) | ALDH1A1TSHRIDO1AGXTPTGS2 | |
| SCHEMBL9679767 | 0.78 | TSHR (0.52) | TSHRIDO1AGXTPTGS2LMNA | |
| SCHEMBL198803 | 0.78 | ERN1 (0.47) | IDO1AGXTPTGS2ERN1MAOB | |
| SCHEMBL11310162 | 0.78 | ESR1 (0.48) | ALDH1A1TSHRIDO1AGXTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8765752-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031936-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| US-8629102-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8557766-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-8383642-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20110092531-A1 | Novel Spiropiperidine Compounds | ELI LILLY AND COMPANY (US) | 2011-04-21 | — | — | US | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| WO-1992014706-A1 | CYCLOPENTANE-DERIVED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092531-A1 | Novel Spiropiperidine Compounds | REN, SLC5A1, SLC5A2 | TRPA1 465/4885ALDH1A1 564/4885TSHR 1199/4885 |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | TRPA1 574/4885ALDH1A1 3399/4885TSHR 394/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | TRPA1 665/4885ALDH1A1 3072/4885TSHR 387/4885 |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | TRPA1 118/4885ALDH1A1 2526/4885TSHR 516/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | TRPA1 722/4885ALDH1A1 3218/4885TSHR 421/4885 |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | PPARD, PPARG, PPARA | TRPA1 2736/4885ALDH1A1 1823/4885TSHR 114/4885 |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | GPR119, GPR27, GPR65 | TRPA1 118/4885ALDH1A1 2508/4885TSHR 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.